Oklahoma
329,764
Registered Patient Population |
8.33%
of Total Population Represented by Patients |
2,073
Total Medical Retail Locations Currently in Operation |
159 : 1
Patients : Retail |
Medical cannabis is legal in Oklahoma. Patients may possess up to eight ounces of medical cannabis flower and one ounce of concentrated medical cannabis, and may also cultivate up to six mature plants with another six immature plants. Patients and caregivers may purchase up to three ounces at a time from dispensaries. Oklahoma allows out of state patients with a valid medical cannabis card to apply for a 30 day temporary card for a registration fee of $100.
 Patient Rights and Civil Protection |
86/100 |
|
| Arrest Protection |
40/40 |
| Affirmative Defense |
15/15 |
| Parental Rights Protections |
10/10 |
| DUI Protections |
0/5 |
| Employment Protections |
4/5 |
| Explicit Privacy Standards |
4/7 |
| Housing Protections |
4/5 |
| Does Not Create New Criminal Penalties for Patients |
4/5 |
| Organ Transplants |
5/5 |
| Reciprocity |
0/3 |
|
|
Access to Medicine |
77/100 |
|
| Allows Distribution Programs |
26/40 |
| – Allows Access to Dried Flowers |
15/15 |
| – Allows Delivery |
0/5 |
| – No Sales Tax or Reasonable Sales Tax |
1/5 |
| – Allows for a Reasonable Number of Dispensaries |
5/5 |
| – Does Not Require Vertical Integration |
2/2 |
| – Ownership/Employment Restrictions |
1/2 |
| – Provisions for Labor Standards |
0/2 |
| – Environmental Impact Regulations |
0/2 |
| – Choice of Dispensary Without Restrictions |
2/2 |
| Noncommercial Cultivation |
15/20 |
| – Personal Cultivation |
15/15 |
| – Collective Gardening |
0/5 |
| Explicit Right to Edibles/Concentrates/Other Forms |
8/10 |
| Does not Impose Bans or Limits on THC |
10/10 |
| Does not Impose Bans on CBD |
10/10 |
| Local Bans/Zoning |
8/10 |
|
|
Ease of Navigation |
95/100 |
|
| Comprehensive Qualifying Conditions |
50/50 |
| Adding New Conditions |
10/10 |
| – Law/Regulations Allow for New Conditions |
5/5 |
| – System Works for Adding New Conditions |
5/5 |
| Reasonable Access for Minors |
7/10 |
| Reasonable Caregiver Background Checks |
4/4 |
| Number of Caregivers |
2/2 |
| Patient/Practitioner-Focused Task Force or Advisory Board |
2/2 |
| Reasonable Fees (Patients and Caregivers) |
10/10 |
| Allows Multiple-Year Registrations |
0/2 |
| Reasonable Physician Requirements |
5/5 |
| Does Not Classify Cannabis as a Medicine of Last Resort |
5/5 |
|
|
Functionality |
90/100 |
|
| Patients Able to Access Medicine at Dispensaries or by Cultivation |
50/50 |
| No Significant Administrative or Supply Problems |
14/15 |
| Patients Can Receive Legal Protections Within Reasonable Time Frame of Doctor's Recommendation |
7/10 |
| Reasonable Possession Limits |
5/5 |
| Reasonable Purchase Limits |
5/5 |
| Allows Patients to Medicate Where They Choose |
3/5 |
| Covered by Insurance/State Health Aid |
1/3 |
| Financial Hardship (Fee Waivers/Discount Medicine) |
5/7 |
|
|
Consumer Safety and Provider Requirements |
55/100 |
|
| Dispensing |
17/25 |
| Staff Training |
1/5 |
| Standard Operating Procedures |
2.5/5 |
| – Facility Sanitary Conditions |
0/1.25 |
| – Storage Protocols |
0/1.25 |
| – Reasonable Security Protocols |
1.25/1.25 |
| – Inventory Control |
1.25/1.25 |
| Recall Protocol and Adverse Event Reporting |
3/5 |
| Product Labeling |
5.0/5 |
| – Product Contents, Including Source Material Identification |
1.67/1.67 |
| – Allergens |
1.67/1.67 |
| – Potency/Compound Identification |
1.67/1.67 |
| Required Testing |
5/5 |
| – Active Compound Identification |
1.67/1.67 |
| – Contaminants |
1.67/1.67 |
| – Potency |
1.67/1.67 |
| Grow/Cultivation |
14/25 |
| Staff Training |
1/5 |
| Standard Operating Procedures |
3/5 |
| – Facility and Equipment Sanitary Conditions |
0/0.71 |
| – Workforce Safety Protocols |
0/0.71 |
| – Storage Protocols (Short-Term and Long-Term Storage) |
0/0.71 |
| – Reasonable Security Protocols |
0.7/0.71 |
| – Batch and Lot Tracking |
0.71/0.71 |
| – Disposal/Waste |
0.71/0.71 |
| – Water Management |
0.71/0.71 |
| Pesticide Guidance |
2.5/5 |
| – Pesticide Guidance |
2.5/2.5 |
| – Pesticide Labeling |
0/2.5 |
| Required Testing |
5/5 |
| – Active Ingredient Identification |
1.25/1.25 |
| – Contaminants |
1.25/1.25 |
| – Potency |
1.25/1.25 |
| – Sample Retention |
1.25/1.25 |
| Recall Protocol and Adverse Event Reporting |
3/5 |
| Manufacturing |
16/25 |
| Staff Training |
1/5 |
| Standard Operating Procedures |
3/5 |
| – Facility and Equipment Sanitary Conditions |
1/1 |
| – Workforce Safety Protocols |
0/1 |
| – Storage Protocols |
0/1 |
| – Reasonable Security Protocols |
1/1 |
| – Batch and Lot Tracking |
1/1 |
| Product Labeling |
5/5 |
| – Product Contents, Including Source Material Identification |
1.67/1.67 |
| – Allergens |
1.67/1.67 |
| – Potency and Compound Information |
1.67/1.67 |
| Required Testing |
4/5 |
| – Active Ingredient Identification |
1/1 |
| – Contaminants |
1/1 |
| – Potency |
1/1 |
| – Shelf Life Testing |
0/1 |
| – Sample Retention |
1/1 |
| Recall Protocol and Adverse Event Reporting |
3/5 |
| Laboratory Operations |
8/25 |
| Staff Training |
1/5 |
| Method Validation in Accordance with AHP Guidelines |
0/5 |
| Result Reporting |
0/5 |
| Independent or Third Party |
5/5 |
| Standard Operating Procedures and Protocols |
2/5 |
| – Equipment and Instrument Calibration |
0/0.83 |
| – Sample Tracking |
0.83/0.83 |
| – Facility and Equipment Sanitary Conditions |
0/0.83 |
| – Disposal/Waste |
0.83/0.83 |
| – Storage Protocols |
0/0.83 |
| – Workforce Safety Protocols |
0/0.83 |
|
|
Covid Response |
14/20
|
|
| Delivery Available? |
0/6
|
| Curbside Pickup Available? |
2/2
|
| Medical Cannabis Essential? |
7/7
|
| Telemedicine Available? |
5/5
|
| Covid Response |
14/20
|
| Delivery Available? |
0/6
|
| Curbside Pickup Available? |
2/2
|
| Medical Cannabis Essential? |
7/7
|
| Telemedicine Available? |
5/5
|
|
| Excerpted from ASA's 2020 State of the States Report. |
In This Section
In April of 2015 Gov. Fallin signed HB 2154, Katie and Cayman's Law, which allows physicians in Oklahoma to recommend a clinical trial with high-CBD cannabis oil to minors suffering from a severe epilepsy disorder. The trial is to be administered at University medical centers. The bill makes no allowance for the production, distribution or analysis of the CBD oil.
HB 2154, Katie and Cayman's Law, creates an exemption for the possession and use of CBD-rich cannabis oil from the criminal definition of marijuana in limited circumstances. Only patients aged 18 or younger with severe epilepsy disorder are eligible for legal protections after the patient obtains a recommendation for CBD oil from a physician. The law requires that the CBD oil be no more than 0.3 % THC. The law also states that the CBD oil for these studies must come from a FDA-approved source.
Any physician licensed doctor or osteopath treating patients with severe forms of epilepsy may serve as the principal investigator in clinical trials of CBD oil.
The State of Medical Marijuana in Oklahoma
